Sulfonamide hydroxamates

Details Sulfonamide hydroxamates Sulfonamide hydroxamates

2005-01-18

2005-01-18

Chang, Celia (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Radical -xh acid, or anhydride, acid halide or salt thereof...

C514S222200, C514S237800, C514S255030, C514S331000, C514S357000, C514S438000, C544S059000, C544S106000, C544S398000, C546S229000, C546S266000, C549S074000, C549S315000

Reexamination Certificate

active

06844366

ABSTRACT:
This invention relates to certain sulfonamide derivatives that are inhibitors of procollagen C-proteinase, pharmaceutical compositions containing them, methods for their use and methods for preparing these compounds.

REFERENCES:
patent: 5455258 (1995-10-01), MacPherson et al.
patent: 5506242 (1996-04-01), MacPherson et al.
patent: 5552419 (1996-09-01), MacPherson et al.
patent: 5646167 (1997-07-01), MacPherson et al.
patent: 5753653 (1998-05-01), Bender et al.
patent: 5770624 (1998-06-01), Parker
patent: 0 606 046 (1994-07-01), None
patent: 0 915 086 (1997-12-01), None
patent: 10204054 (1998-08-01), None
patent: WO 9705865 (1997-02-01), None
patent: WO 9843963 (1998-10-01), None
patent: WO 9850348 (1998-11-01), None
McCullough “Bleomycin-induced diffuse interstitial pulmonary fibrosis in baboons” CA 88:146753 (1978).*
Raghow et al. “Profiles of steady state . . . ” CA 104:15995 (1986).*
Watanabe et al. “Type Ili procollage . . . ” CA 104:32553 (1986).*
Kato et al. “Bleomycin-induced arthritis . . . ” CA 128:162624 (1998).*
Parizada et al. “Protective effects of . . . ” CA 116:192043 (1992).*
Gonnella et al. “Bioactive conformation . . . ” CA 122:177675 (1995).*
Gonnella et al. “Bioactive conformation of . . . ” CA 124:224712 (1996).*
MacPherson et al. “Preparation of heteroarylsulfonamido . . . ” CA 124:289286 (1996).*
Watanabe et al. “Preparation of N-sulfonylaminl . . . ” CA 127:162119 (1997).*
Clare et al. “Protease inhibitors . . . ” CA 135:133815 (2001).*
MacPherson, et al.,Journal of Medicinal Chemistry, vol. 40:16 (1997) pp 2525-2532, “Discovery of CGS 27023A, a Non-Peptidic, Potent, and Orally Active Stromelysin Inhibitor That Blocks Cartilage Degradation in Rabbits”.
Jeng, et al.,Bioorganic and Medicinal Chemistry Letter, vol. 8:8 (1998) pp 897-902, “Sulphonamide-based hydroxamic acids as potent inhibitors of mouse macrophase metalloelastase”.
Fish r, t al.,B richt d r Deutsch n Chemisch n G s llschaft, vol. 49 (1916) pp 1355-1366, “Bildung aktiver, sekunärer Aminosaurenaus Halogenaäuren und primären Aminen”.
Chemical Abstract No. No. 6563F (XP-002135506), vol. 54:7 (Apr. 10, 1960) for Budeskinsky, et al., Ceskoslov, Farm., vol. 8 (1959) pp 161-166 “Synthetic antidiabetics. II. N-Tosylated amino acids and their N-alkyl derivatives”.
Gellert, et al.,Australian Journal of Chemistry, vol. 37:4 (1984) pp 819-829, “Stereospecific synthesis of hexahydrobenzopyrroloisoquinoline and tetrahydrobenzisoquinoline derivatives”.
Gonzales-Cameno, et al.,Tetrahedron, vol. 50:37 (1994) pp 10971-10982, “Preparation of a 3-Phenyl-4(3H)-isoquinolinone and its transformation in 12(11H)-Benzo[c] phenanthridinone Derivatives. Crystal structure determinations”.
Jurczak, et al.,Tetrahedron, vol. 54:22 (1998) pp 6051-6064, “Effective and Mild Method for Preparation of Optically Active α-Amino Aldehydes via TEMPO Oxidation”.
Dankwardt, et al.,Synlett, No. 7 (Jul. 1997) pp 854-856, Solid phase synthesis of N-alkyl sulphonamides.

Affiliated with

Also associated with

Rating

Sulfonamide hydroxamates does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Sulfonamide hydroxamates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfonamide hydroxamates will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3435237